Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generex Likes Chances For Partnering AE37 Breast Cancer Vaccine

Executive Summary

The vaccine trains specialized immune cells to act against a HER2 peptide. Created using Antigen Express’ Ii-Key Hybrid platform, Generex says AE37 has none of the restrictions that will limit the market potential of other HER2 peptide vaccines in development.

Advertisement

Related Content

Making Gains Against Triple-Negative Breast Cancer
Sign Of The Times: Late-Stage Cancer Vaccines On Display At ASCO

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS055551

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel